We could not find any results for:
Make sure your spelling is correct or try broadening your search.
New York, NY, April 23, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB) (“10X III”), announced today that New York Stock Exchange Regulation, Inc., by...
New York, NY, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB, VCXB.U, VCXB WS) (“10X III”), announced today that NYSE Regulation (“NYSER”), by...
NEW YORK, NY (United States), Jan. 08, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (“10X III”) (NYSE American:VCXB), a publicly traded special purpose acquisition...
New York, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB) (“10X III”), announced today that New York Stock Exchange Regulation, Inc., by...
New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U, VCXB, VCXB WS) (“10X III”) today announced that it is transferring the listing of its...
Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing...
Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.83 | -6.95725062867 | 11.93 | 11.93 | 10.76 | 3 | 11.1 | CS |
4 | 0.31 | 2.87303058387 | 10.79 | 11.93 | 10.76 | 57 | 11.09458988 | CS |
12 | 1.37 | 14.0801644399 | 9.73 | 13 | 9.73 | 191 | 10.96264958 | CS |
26 | 1.39 | 14.3151390319 | 9.71 | 13 | 9.66 | 257 | 10.8577937 | CS |
52 | 0.49 | 4.61828463713 | 10.61 | 13 | 9.5 | 235 | 10.84452972 | CS |
156 | 0.49 | 4.61828463713 | 10.61 | 13 | 9.5 | 235 | 10.84452972 | CS |
260 | 0.49 | 4.61828463713 | 10.61 | 13 | 9.5 | 235 | 10.84452972 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions